TGFB1 and neoplasm: However, the inhibition of TGFβ in breast cancer bone metastases with an oncolytic adenovirus-expressing soluble TGFβ receptor II fused with human immunoglobulin Fc fragment reduced M2-like osteoclast activity and tumor progression [47].